Simcere Pharmaceutical (HKG:2096) posted profit attributable to equity shareholders of 1.34 billion yuan for 2025, up 86% from 722 million yuan a year earlier, according to a Tuesday Hong Kong bourse filing.
Shares of the pharmaceutical firm were down 1% in recent trade.
Earnings per share came in at 0.54 yuan from 0.29 yuan a year earlier.
Revenue rose 16.5% to 7.73 billion yuan from 6.64 billion yuan in 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.